Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)
Latest Information Update: 10 Nov 2023
Price :
$35 *
At a glance
- Drugs Keynatinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Medolution
- 04 Nov 2023 Planned End Date changed from 22 Jul 2024 to 22 Jul 2025.
- 04 Nov 2023 Planned primary completion date changed from 22 Apr 2024 to 22 Apr 2025.
- 17 Apr 2022 Planned End Date changed from 22 Jul 2022 to 22 Jul 2024.